Mika Raises More Than EUR10M in Series A Funding
Summary
Fosanis, a Berlin, Germany-based digital health company which develops Mika, a prescription DTx for all oncological indications, closed a series A funding round of more than €10m. The company intend stop use the funds to expand into international terrain. Founded in 2017 by Dr Gandolf Finke and Dr Jan Simon Raue, Fosanis has developed the AI-powered DTx Mika in collaboration with oncological research institutions and cancer centres such as the University of Leipzig Medical Center and Charité Berlin. Mika is a personalised digital therapeutic (DTx) platform in oncology, which delivers evidence-based digital interventions with a view to supporting cancer patients in coping with the challenges of the disease and treatment process. Daily check-ups – so-called ePROs = electronic patient-reported outcomes – allow continuous tracking of distress levels and symptoms, while a personalised coaching programme provides scientifically validated multi-media elements and psychooncological interventions.
Funding
Review available funding amount, funding date, investors, and linked company information related to Mika Raises More Than EUR10M in Series A Funding in the interactive ISVWorld profile.